Minor Structural Changes in a Mutated Human Melanoma Antigen Correspond to Dramatically Enhanced Stimulation of a CD4+ Tumor-infiltrating Lymphocyte Line
- 31 May 2002
- journal article
- Published by Elsevier in Journal of Molecular Biology
- Vol. 319 (2) , 449-461
- https://doi.org/10.1016/s0022-2836(02)00370-4
Abstract
No abstract availableKeywords
Funding Information
- Arthritis Foundation (AI49564, AI36900)
- National Institutes of Health (AI49564, AI36900)
This publication has 58 references indexed in Scilit:
- The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunityTrends in Immunology, 2001
- MHC Class II–Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine DesignJournal of Immunotherapy, 2001
- The dendritic cell and human cancer vaccinesCurrent Opinion in Immunology, 2000
- CD4+ T Cells in Adoptive Immunotherapy and the Indirect Mechanism of Tumor RejectionCritical Reviews in Immunology, 2000
- CD4 T Cells and Their Role in Antitumor Immune ResponsesThe Journal of Experimental Medicine, 1999
- Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1International Journal of Cancer, 1999
- T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactionsNature, 1998
- Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative TumorsThe Journal of Experimental Medicine, 1998
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaNature Medicine, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998